News on VWF from BioPortfolio.com http://www.BioPortfolio.com Consolidated VWF news from BioPortfolio.com Wed, 10 Feb 2010 06:34:52 GMT en SWIFT Haemophilia Drug Trials Beginhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028643&HITNO=0&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028643&THISHREF=http://c.moreover.com/click/here.pl%3fz2532796290%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4028643&HITNO=0&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4028643&THISHREF=http://c.moreover.com/click/here.pl%3fz2532796290%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaceutical Technology: Life Sciences: Reports outline life sciences research from Baxter BioSciencehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026501&HITNO=1&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026501&THISHREF=http://c.moreover.com/click/here.pl%3fz2530923129%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026501&HITNO=1&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026501&THISHREF=http://c.moreover.com/click/here.pl%3fz2530923129%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: Global SWIFT Studies Will Evaluate Safety and Efficacy of CSL Behring's Biostate(R) for von Willebrand Diseasehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019782&HITNO=2&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019782&THISHREF=http://c.moreover.com/click/here.pl%3fz2526477601%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019782&HITNO=2&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019782&THISHREF=http://c.moreover.com/click/here.pl%3fz2526477601%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmiWeb: Endothelial dysfunction linked to clopidogrel resistance pre-PCIhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3957338&HITNO=3&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3957338&THISHREF=http://c.moreover.com/click/here.pl%3fz2494925965%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3957338&HITNO=3&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3957338&THISHREF=http://c.moreover.com/click/here.pl%3fz2494925965%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedWire News: Octapharma's Wilate Plasma Given Orphan Drug Statushttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3922806&HITNO=4&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3922806&THISHREF=http://c.moreover.com/click/here.pl%3fz2476229176%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3922806&HITNO=4&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3922806&THISHREF=http://c.moreover.com/click/here.pl%3fz2476229176%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaceutical Technology: Medical News: Octapharma Receives Orphan Drug Exclusivity Approval For Wilate(R) - A Replacement Therapy Developed Specifically For Von Willebrand Diseasehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3907207&HITNO=5&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3907207&THISHREF=http://c.moreover.com/click/here.pl%3fz2467339608%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3907207&HITNO=5&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3907207&THISHREF=http://c.moreover.com/click/here.pl%3fz2467339608%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioFind: Octapharma Receives Orphan Drug Exclusivity Approval For Wilate(R) - A Replacement Therapy Developed Specificahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3907037&HITNO=6&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3907037&THISHREF=http://c.moreover.com/click/here.pl%3fz2467234041%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3907037&HITNO=6&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3907037&THISHREF=http://c.moreover.com/click/here.pl%3fz2467234041%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: Octapharma Receives Orphan Drug Exclusivity Approval For Wilate - A Replacement Therapy Developed Specifically For Von Willebrand Diseasehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3906364&HITNO=7&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3906364&THISHREF=http://c.moreover.com/click/here.pl%3fz2466883171%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3906364&HITNO=7&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3906364&THISHREF=http://c.moreover.com/click/here.pl%3fz2466883171%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaceutical Online: Octapharma receives Orphan Drug Exclusivity Approval for wilate(R) - the First Replacement Therapy Developed Shttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3904615&HITNO=8&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3904615&THISHREF=http://c.moreover.com/click/here.pl%3fz2465753367%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3904615&HITNO=8&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3904615&THISHREF=http://c.moreover.com/click/here.pl%3fz2465753367%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comcompaniesandmarkets.com: Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specificahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3904026&HITNO=9&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3904026&THISHREF=http://c.moreover.com/click/here.pl%3fz2465500928%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3904026&HITNO=9&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3904026&THISHREF=http://c.moreover.com/click/here.pl%3fz2465500928%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Octapharma Receives Orphan Drug Exclusivity Approval For Wilate(r) - The First Replacement Therapy Developed Shttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3903527&HITNO=10&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3903527&THISHREF=http://c.moreover.com/click/here.pl%3fz2465238438%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3903527&HITNO=10&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3903527&THISHREF=http://c.moreover.com/click/here.pl%3fz2465238438%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedia Relations and Event Management: Octapharma Receives Orphan Drug Exclusivity Approval for wilate - A Replacement Therapy Developed Specificallyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3903354&HITNO=11&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3903354&THISHREF=http://c.moreover.com/click/here.pl%3fz2465164414%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3903354&HITNO=11&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3903354&THISHREF=http://c.moreover.com/click/here.pl%3fz2465164414%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Octapharma receives Orphan Drug Exclusivity Approval for wilate(R) - the First Replacement Therapy Developed Shttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3903286&HITNO=12&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3903286&THISHREF=http://c.moreover.com/click/here.pl%3fz2465123627%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3903286&HITNO=12&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3903286&THISHREF=http://c.moreover.com/click/here.pl%3fz2465123627%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Octapharma Receives Orphan Drug Exclusivity Approval for wilate - A Replacement Therapy Developed Specificallyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3903197&HITNO=13&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3903197&THISHREF=http://c.moreover.com/click/here.pl%3fz2465064331%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3903197&HITNO=13&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3903197&THISHREF=http://c.moreover.com/click/here.pl%3fz2465064331%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Diseasehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3902353&HITNO=14&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3902353&THISHREF=http://c.moreover.com/click/here.pl%3fz2464729920%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3902353&HITNO=14&MSIZE=46&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=VWF&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3902353&THISHREF=http://c.moreover.com/click/here.pl%3fz2464729920%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSan Antonio Business Journal: